Renovorx Inc (RNXT)
$1
Live
Performance
- $0.99$1.00$1.00
0.99%
Downside
Day's Volatility :0.99%
Upside
0.0%
- $0.53$2.35$1.00
46.94%
Downside
52 Weeks Volatility :77.42%
Upside
57.45%
Returns
| Period | Renovorx Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -15.25% | 0.0% |
6 Months | -18.7% | 0.0% |
1 Year | -9.91% | 0.0% |
3 Years | -82.99% | -23.0% |
Highlights
Market Capitalization | 24.0M |
Book Value | $0.39 |
Earnings Per Share (EPS) | -0.6 |
Wall Street Target Price | 5.69 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -70.08% |
Return On Equity TTM | -155.12% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -11.4M |
Diluted Eps TTM | -0.6 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.4 |
EPS Estimate Next Year | -0.41 |
EPS Estimate Current Quarter | -0.1 |
EPS Estimate Next Quarter | -0.09 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 469.0%
Technicals Summary
Sell
Neutral
Buy
Renovorx Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Renovorx Inc | -2.91% | -18.7% | -9.91% | -82.99% | -86.23% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Renovorx Inc | NA | NA | NA | -0.4 | -1.55 | -0.7 | NA | 0.39 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Renovorx Inc | Buy | $24.0M | -86.23% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Renovorx Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 96.7%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 127.8%
Institutional Holdings
ADAR1 Capital Management LLC
1.48%Geode Capital Management, LLC
0.60%Watch Point Trust Co
0.41%Millennium Management LLC
0.36%Vanguard Group Inc
0.24%Charles Schwab Investment Management Inc
0.21%
Company Information
renovorx is a medical device company headquartered in silicon valley, california. we are developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral vascular system. the ability to deliver these materials at high concentration to specific vasculature, safely and without perfusion overlap to other regions, is a central paradigm of our technology. we have received fda clearance for the renovocath™ rc120 and are now introducing our innovative technology to the clinical market. renovorx is a highly motivated team with broad experience and an exciting vision for the future of targeted delivery. we are backed by a broad medical advisory board and a strong board of directors. please contact us at info@renovorx.com to learn more.
Organization | Renovorx Inc |
Employees | 8 |
CEO | Dr. Ramtin Agah M.D. |
Industry | Miscellaneous |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$1.00
+0.0%
Invesco Bulletshares 2025 Hi
$1.00
+0.0%
Schwab International Dividend Equity Etf
$1.00
+0.0%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$1.00
+0.0%
Lightpath Technologies Inc
$1.00
+0.0%
Vaneck Vectors Global Alternative Energy Etf
$1.00
+0.0%
First Trust Flexible Municipal High Income Etf
$1.00
+0.0%
Drx Dly Reg Bank Bull 3x
$1.00
+0.0%
Graniteshares 2x Long Pltr Daily Etf
$1.00
+0.0%